Week in Review: CFDA Begins Reform of China Drug Approval Process

The CFDA has issued the first set of new policies that are designed to reduce its very long waiting times in China for drug approvals; China's drug sales will reach $150-$180 billion in 2020, a CAGR of 6-9%, according to IMS; Nantong Jinghua Pharma struck a $50 million deal for two anti-cancer mAbs from Kadmon Corporation of New York; Lee's Pharma in-licensed Greater China rights to a potential liver cancer treatment from Tragara Pharma of San Diego: Tianjin Tasly and Taikang Life Insurance launched a $784 million China healthcare fund; LYFE Capital closed its first China healthcare fund at $298 million; Beijing's BeiGene was given the 2015 R&D Achievement of the Year award by BayHelix; Fresenius Medical Care, a German renal care company, opened its new China Design Center in Shanghai; and the Shenzhen Cell Bank and Shenzhen (Beike) Regional Cell Preparation Center formed a cell therapy translation base with 11 Shenzhen hospitals. More details.... Stock Symbols: (SHZ: 002349) (HK: 950) (SHA: 600535) Share this with colleagues: // //  
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.